109 related articles for article (PubMed ID: 28666770)
1. Marfan Syndrome (MFS): Visual Diagnosis and Early Identification.
Temples HS; Rogers CR; Willoughby D; Holaday B
J Pediatr Health Care; 2017; 31(5):609-617. PubMed ID: 28666770
[No Abstract] [Full Text] [Related]
2. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
Teixido-Tura G; Forteza A; Rodríguez-Palomares J; González Mirelis J; Gutiérrez L; Sánchez V; Ibáñez B; García-Dorado D; Evangelista A
J Am Coll Cardiol; 2018 Oct; 72(14):1613-1618. PubMed ID: 30261963
[TBL] [Abstract][Full Text] [Related]
3. Correspondence regarding: Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome by Bhatt et al.
O'Rourke MF; Adji A; Weber T
Vasc Med; 2016 Feb; 21(1):70. PubMed ID: 26669325
[No Abstract] [Full Text] [Related]
4. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome.
Bhatt AB; Buck JS; Zuflacht JP; Milian J; Kadivar S; Gauvreau K; Singh MN; Creager MA
Vasc Med; 2015 Aug; 20(4):317-25. PubMed ID: 25795452
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes.
Sandor GG; Alghamdi MH; Raffin LA; Potts MT; Williams LD; Potts JE; Kiess M; van Breemen C
Int J Cardiol; 2015 Jan; 179():470-5. PubMed ID: 25465809
[TBL] [Abstract][Full Text] [Related]
6. Aortic biomechanical properties in pediatric patients with the Marfan syndrome, and the effects of atenolol.
Reed CM; Fox ME; Alpert BS
Am J Cardiol; 1993 Mar; 71(7):606-8. PubMed ID: 8438752
[No Abstract] [Full Text] [Related]
7. Atenolol versus Losartan in Marfan's Syndrome.
Mallat Z; Tedgui A
N Engl J Med; 2015 Mar; 372(10):980. PubMed ID: 25738683
[No Abstract] [Full Text] [Related]
8. Atenolol versus Losartan in Marfan's Syndrome.
Treasure T; Pepper J; Mohiaddin R
N Engl J Med; 2015 Mar; 372(10):978-9. PubMed ID: 25738682
[No Abstract] [Full Text] [Related]
9. Atenolol versus Losartan in Marfan's Syndrome.
Ziganshin BA; Mukherjee SK; Elefteriades JA
N Engl J Med; 2015 Mar; 372(10):977-8. PubMed ID: 25738681
[No Abstract] [Full Text] [Related]
10. Atenolol versus Losartan in Marfan's Syndrome.
Lacro RV; Dietz HC; Mahony L
N Engl J Med; 2015 Mar; 372(10):980-1. PubMed ID: 25738680
[No Abstract] [Full Text] [Related]
11. Of Marfan's syndrome, mice, and medications.
Bowen JM; Connolly HM
N Engl J Med; 2014 Nov; 371(22):2127-8. PubMed ID: 25405389
[No Abstract] [Full Text] [Related]
12. [Recommendations for the medical management of aortic complications of Marfan's syndrome].
Jondeau G; Barthelet M; Baumann C; Bonnet D; Chevallier B; Collignon P; Dulac Y; Edouard T; Faivre L; Germain D; Khau Van Kien P; Lacombe D; Ladouceur M; Lemerrer M; Leheup B; Lupoglazoff JM; Magnier S; Muti C; Plauchu PH; Raffestin B; Sassolas F; Schleich JM; Sidi D; Themar-Noël C; Varin J; Wolf JE; ;
Arch Mal Coeur Vaiss; 2006 May; 99(5):540-6. PubMed ID: 16802751
[No Abstract] [Full Text] [Related]
13. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.
Forteza A; Evangelista A; Sánchez V; Teixidó-Turà G; Sanz P; Gutiérrez L; Gracia T; Centeno J; Rodríguez-Palomares J; Rufilanchas JJ; Cortina J; Ferreira-González I; García-Dorado D
Eur Heart J; 2016 Mar; 37(12):978-85. PubMed ID: 26518245
[TBL] [Abstract][Full Text] [Related]
14. AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?
Mallat Z; Daugherty A
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):e10-2. PubMed ID: 25550201
[No Abstract] [Full Text] [Related]
15. [Drugs news].
Lengellé C; Bejan-Angoulvant T; Beau-Salinas F; Jonville-Béra AP
Arch Pediatr; 2015 Nov; 22(11):1200-6. PubMed ID: 26385645
[No Abstract] [Full Text] [Related]
16. Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.
Hibender S; Franken R; van Roomen C; Ter Braake A; van der Made I; Schermer EE; Gunst Q; van den Hoff MJ; Lutgens E; Pinto YM; Groenink M; Zwinderman AH; Mulder BJ; de Vries CJ; de Waard V
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1618-26. PubMed ID: 27283746
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular characteristics in Marfan syndrome and their relation to the genotype.
De Backer J
Verh K Acad Geneeskd Belg; 2009; 71(6):335-71. PubMed ID: 20232788
[TBL] [Abstract][Full Text] [Related]
18. miR-29b participates in early aneurysm development in Marfan syndrome.
Merk DR; Chin JT; Dake BA; Maegdefessel L; Miller MO; Kimura N; Tsao PS; Iosef C; Berry GJ; Mohr FW; Spin JM; Alvira CM; Robbins RC; Fischbein MP
Circ Res; 2012 Jan; 110(2):312-24. PubMed ID: 22116819
[TBL] [Abstract][Full Text] [Related]
19. Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.
Van Driest SL; Sleeper LA; Gelb BD; Morris SA; Dietz HC; Forbus GA; Goldmuntz E; Hoskoppal A; James J; Lee TM; Levine JC; Li JS; Loeys BL; Markham LW; Meester JAN; Mital S; Mosley JD; Olson AK; Renard M; Shaffer CM; Sharkey A; Young L; Lacro RV; Roden DM
J Pediatr; 2020 Jul; 222():213-220.e5. PubMed ID: 32586526
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome.
Rios AS; Silber EN; Bavishi N; Varga P; Burton BK; Clark WA; Denes P
Am Heart J; 1999 Jun; 137(6):1057-61. PubMed ID: 10347331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
